Nutriband Inc. (NASDAQ: NTRB) announced that CEO Gareth Sheridan published a letter to shareholders marking the fifth anniversary of the company’s listing on the Nasdaq Capital Market. The letter, released on Oct. 1, 2021, reviews key milestones achieved since the listing and outlines upcoming priorities for the specialty pharmaceutical company.
According to the announcement, Sheridan highlighted the advancement of AVERSA(TM) Fentanyl from feasibility through commercial manufacturing scale-up, expanded patent protection, and ongoing engagement with the U.S. Food and Drug Administration. The company’s lead product under development is an abuse-deterrent fentanyl patch that incorporates its proprietary AVERSA(TM) abuse-deterrent technology. This technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential and can be incorporated into any transdermal patch.
Sheridan noted that the company’s priorities ahead include manufacturing clinical supplies for a Human Abuse Liability study, filing an Investigational New Drug application, initiating clinical studies, and advancing AVERSA(TM) Fentanyl toward a New Drug Application filing. These steps are critical for bringing the product to market and addressing the ongoing public health crisis related to opioid abuse.
The five-year anniversary of Nutriband’s Nasdaq listing provides an opportunity to reflect on the company’s progress and its future trajectory. For investors, the letter signals continued momentum in the development of AVERSA(TM) Fentanyl and a clear roadmap for regulatory milestones. The company’s focus on abuse-deterrent technology aligns with broader efforts to combat opioid misuse, a pressing issue that has drawn significant attention from regulators, healthcare providers, and the public.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its website is www.nutriband.com. The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB. To view the full press release, visit https://ibn.fm/Bg8PU.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which delivers services including editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. These services aim to help companies reach a wide audience of investors, influencers, consumers, journalists, and the general public.
